Broker Name: Impact Capital Asset Management Pte Ltd
Date of Report: 13 April 2026
Excerpt from Impact Capital Asset Management report
Report Summary
- Stock Focus: China Medical System Holdings Limited
- Action: NON-RATED (Results Update)
- Last Traded Price: S\$2.40 (as of 13 April 2026)
- 12-month Target Price: Not Available
Key Highlights:
- CMS’s revenue rose 9.9% to RMB8,212.1m in FY2025; innovative and exclusive products now make up 59.8% of direct-sales revenue.
- Gross profit increased 8.3%, but reported profit fell 10.5% to RMB1,443.3m. Normalized profit, excluding a one-off tax payment, increased 3.6% to RMB1,775.5m.
- Operating cash flow declined sharply to RMB758.4m, and cash conversion cycle worsened to 136 days, highlighting cash quality concerns.
- Balance sheet remains strong with low leverage and RMB2,701.4m in cash, but liquidity is increasingly tied up in receivables and working capital.
- The transition towards innovative products is real, but margin recovery and cash conversion remain the key proof points for the next 12 months.
- Dividend payout ratio was 45.8%, but future capital allocation will require tighter discipline as cash generation has weakened.
- No explicit BUY or SELL call; investors should monitor margin quality, cash conversion, and the performance of new platforms in FY2026 for further actionable insights.
Above is an excerpt from a report by Impact Capital Asset Management Pte Ltd. Clients of Impact Capital Asset Management can be the first to access the full report from the Impact Capital Asset Management website: https://www.icam.com.sg
